Introduction: Only a minority of people living with mental health problems are getting professional help. As digitalisation moves on, the possibility of providing internet/mobile-based interventions (IMIs) arises. One type of IMIs are fully automated conversational software agents (chatbots). Software agents are computer programs that can hold conversations with a human by mimicking a human conversational style. Software agents could deliver low-threshold and cost-effective interventions aiming at promoting psychological well-being in a large number of individuals. The aim of this trial is to evaluate the clinical effectiveness and acceptance of the brief software agent-based IMI SISU in comparison with a waitlist control group.
Methods And Analysis: Within a two-group randomised controlled trial, a total of 120 adult participants living with low well-being (Well-being Scale/WHO-5) will be recruited in Germany, Austria and Switzerland. SISU is based on therapeutic writing and acceptance and commitment therapy-based principles. The brief intervention consists of three modules. Participants work through the intervention on 3 consecutive days. Assessment takes place before (t1), during (t2) and after (t3) the interaction with SISU, as well as 4 weeks after randomisation (t4). Primary outcome is psychological well-being (WHO-5). Secondary outcomes are emotional well-being (Flourishing Scale), psychological flexibility (Acceptance and Action Questionnaire-II), quality of life (Assessment of Quality of Life -8D), satisfaction with the intervention (Client Satisfaction Questionnaire-8) and side effects (Inventory for the assessment of negative effectsof psychotherapy). Examined mediators and moderators are sociodemographic variables, personality (Big Five Inventory-10), emotion regulation (Emotion Regulation Questionnaire), alexithymia (Toronto Alexithymia Scale-20), centrality of events (Centrality of Events Scale), treatment expectancies (Credibility Expectancy Questionnaire) and technology alliance (Inventory of Technology Alliance-Online Therapy). Data analysis will be based on intention-to-treat principles. SISU guides participants through a 3-day intervention.
Ethics And Dissemination: This trial has been approved by the ethics committee of the Ulm University (No. 448/18, 18.02.2019). Results will be submitted for publication in a peer-reviewed journal and presented at conferences.
Trial Registration: The trial is registered at the WHO International Clinical Trials Registry Platform via the German Clinical Trials Register (DRKS): DRKS00016799 (date of registration: 25 April 2019). In case of important protocol modifications, trial registration will be updated. This is protocol version number 1.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871683 | PMC |
http://dx.doi.org/10.1136/bmjopen-2020-041573 | DOI Listing |
Alzheimers Dement
December 2024
National Cerebral and Cardiovascular Center, Suita, Osaka, Japan.
Background: Cilostazol, a selective type-3 phosphodiesterase inhibitor, ameliorates β-amyloid accumulation by facilitating intramural periarterial drainage.
Method: Patients with mild cognitive impairment were registered in the COMCID study, an investigator-initiated, double-blinded, multi-center, phase-II clinical trial. The primary endpoint was the Mini-Mental State Examination score.
Alzheimers Dement
December 2024
Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Background: Context-specific measures with high content validity are needed to adequately determine psychosocial effects related to screening for cognitive impairment. The objective of this investigation was to examine psychometric properties of the Psychological Consequences of Screening Questionnaire (PCQ), a measure of psychological impact of medical screening, adapted for cognitive screening in primary care.
Methods: Two-hundred adults aged ≥65 recently completing routine, standardized cognitive screening as part of their Medicare Annual Wellness Visit were administered the adapted PCQ measure, comprised of negative (PCQ-Neg) and positive (PCQ-Pos) scales.
Alzheimers Dement
December 2024
University of California San Francisco, San Francisco, CA, USA.
Background: Family caregivers of persons living with dementia (PLWD) in rural areas of the United States (U.S.) are isolated, under-served, and experience poor health outcomes.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
National Center for Geriatrics and Gerontology, Obu, Aichi, Japan.
Background: To enhance the well-being of individuals with dementia, it is crucial to minimize the risk of deterioration in long-term care needs. This study aimed to identify factors and construct predictive models for deterioration in long-term care (LTC) levels in Japanese older adults with Mild Cognitive Impairment (MCI) and dementia.
Method: This retrospective cohort study utilized the data from a memory clinic-based cohort study (NCGG-STORIES) and individual LTC insurance data provided by three municipalities.
Alzheimers Dement
December 2024
University of Michigan, Ann Arbor, MI, USA.
Background: Caregiving, both cross-sectional and longitudinal, is often considered a stressful experience. Less is known about the effect of the caregiving experience or the associated stress on cognitive functioning of the care provider.
Method: Data are drawn from the Social Relations Study (SRS) and the Detroit Area Wellness Network (DAWN) Studies.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!